top of page
Laleh Melstrom

Laleh Melstrom


Surgical Oncologist; Chief of the Division of Surgical Oncology at City of Hope, one of the largest cancer research and treatment organizations in the United States.

Liver Health Foundation is pleased to honor Laleh Golkar Melstrom, MD, MSCI, as the recipient of the “2023 Healthcare Visionary Award.”

Dr. Melstrom is Chief of the Division of Surgical Oncology, Associate Professor of Surgery and Immuno-Oncology, and a surgical oncologist at City of Hope National Medical Center, one of the largest cancer research and treatment organizations in the United States.

A talented surgeon and award-winning instructor and researcher, Dr. Melstrom was educated at Johns Hopkins University. She received her medical degree at Cornell Medical College in New York City, continuing her training at Northwestern Memorial Hospital in Chicago and New York’s Memorial Sloan-Kettering Cancer Center.
Dr. Melstrom held professorships at both Cornell and Robert Wood Johnson Medical School before moving to California. She is certified in robotic surgery and specializes in the treatment of cancers of liver, pancreas, and sarcoma. She has published over 110 scholarly articles. Her research is funded by the National Institutes of Health (NIH) and many foundations. Dr. Melstrom is a sought-after speaker at national and international conferences.

Dr. Melstrom joined City of Hope in March 2015. City of Hope is a leader in minimally invasive and complex surgeries for liver cancer and has one of the best track records for safety and long-term outcomes. Dr Melstrom co-leads the GI disease team at City of Hope and has developed a program of perioperative telemonitoring for patients after discharge from major liver surgery. City of Hope specialists have experience in hepatic arterial infusion (HAI), which delivers cancer-fighting medicine directly to the tumor site for greater effectiveness.

At City of Hope, liver cancer clinicians and researchers collaborate extensively to develop and evaluate new therapies for better survival and quality-of-life outcomes. City of Hope patients have access to a wide variety of clinical trials including new chemotherapy and targeted therapies, hormone therapies, novel surgical techniques, innovative radiation approaches and new prevention strategies. These trials give current patients access to promising, leading-edge therapies and improve overall care for future patients worldwide.

We salute Dr. Melstrom’s unrivaled devotion to her patients and her skill in saving lives.

bottom of page